Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
SOUTH SAN FRANCISCO, Calif. , May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom , Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell Lymphoma…